logo
Why Pune's Cafe Goodluck was shut — All you need to know about FDA inspection, glass piece controversy

Why Pune's Cafe Goodluck was shut — All you need to know about FDA inspection, glass piece controversy

Minta day ago
The famous Cafe Goodluck in Pune is making headlines after the Maharashtra Food and Drug Administration (FDA) temporarily suspended its licence, PTI reported. An official claimed that the major step to shut down Pune's famous eatery was taken over hygiene issues.
"An inspection was conducted, during which some unhygienic conditions were found. We have suspended the eatery's licence until further orders and necessary compliance," PTI quoted FDA Joint Commissioner Suresh Annapure as saying on Sunday.
A few days ago, a video purportedly showing the famous bun maska with a glass piece at the famous eatery went viral. A couple claimed that the glass piece was found in their order at Cafe Goodluck and recorded the footage of the incident, which quickly gained traction on social media.
After taking cognisance of viral reports about a glass piece allegedly found in one of Cafe Goodluck's food items, the FDA inspected the food joint, according to the official. The customer, identified as Aakash Jalagi, reported the matter online to the agency responsible for protecting public health, citing a breach of consumer safety.
'It was my weekly off, and I had planned a small date with my wife at FC Road. We went to Cafe Goodluck and ordered tea along with Bun Maska. When my wife took a bite, she felt a transparent, hard substance in her mouth," Pune Times Mirror quoted the customer, a resident of Dhayari.
Accusing the restaurant of negligence in food preparation, Aakash Jalagi said, 'Initially, we thought it was ice, but on checking, we realised it was a piece of glass. It could have caused serious internal injuries had she swallowed it.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Denial of preferred food to prisoners not rights violation,' says SC; flags disability gaps in jails
'Denial of preferred food to prisoners not rights violation,' says SC; flags disability gaps in jails

Time of India

time2 hours ago

  • Time of India

'Denial of preferred food to prisoners not rights violation,' says SC; flags disability gaps in jails

Representative Image NEW DELHI: The Supreme Court on Tuesday said that not providing "preferred or costly food items" to prisoners, including those with disabilities, does not constitute a violation of fundamental rights. Justices J B Pardiwala and R Mahadevan clarified that while Article 21 of the Constitution extends the right to life to all prisoners, it does not grant them the right to demand personalised or luxurious food choices, PTI reported. The bench emphasised, "Mere non-supply of preferred or costly food items cannot ipso facto be treated as a violation of fundamental State's obligation is to ensure that every inmate, including those with disabilities, receives adequate, nutritious, and medically appropriate food, subject to medical certification." The court stated that prisons are correctional facilities rather than extensions of civil society's comforts. Unless resulting in provable harm to health or dignity, the court noted that withholding non-essential or indulgent items does not violate constitutional or human rights. "Prisons are often regarded as the 'tail-end' of the criminal justice system – historically designed for rigid discipline, harsh conditions, and minimal liberties. While modern penological principles advocate rehabilitation over retribution, the current prison infrastructure and operational systems in India remain grossly inadequate – especially when it comes to meeting the needs of prisoners with disabilities," the verdict stated. These observations arose from an appeal by advocate L Muruganantham, who suffers from Becker muscular dystrophy, challenging a Madras High Court order that awarded him Rs 5 lakh compensation. His imprisonment stemmed from a land dispute between his family and another individual. During his incarceration, he alleged inadequate medical care and insufficient protein-rich food, including eggs, chicken and nuts, on a daily basis. The court acknowledged that while the respondent authorities may not be directly responsible for prison facility deficiencies, these issues highlight the urgent need for prison reforms, particularly regarding disability-sensitive infrastructure and protocols. The court recognised the systematic neglect in prison infrastructure, especially concerning disabled prisoners' needs. "Persons with disabilities must be provided healthcare equivalent to that available in the general community. This includes access to physiotherapy, speech therapy, psychiatric care, and assistive devices, such as wheelchairs, hearing aids, or crutches. Prison authorities are under a duty to coordinate with public healthcare systems to ensure uninterrupted care. Logistical or financial limitations cannot be cited to justify a withdrawal of this obligation," it said. The court found most state prison manuals "outdated" and "uninformed" regarding developments in disability law and rights-based discourse. "They frequently conflate sensory or physical disabilities with mental illness or cognitive decline, thereby eroding the distinct legal right to reasonable accommodation. This conflation promotes harmful stereotypes and obstructs disabled inmates from claiming their lawful entitlements," it noted. The court concluded that the state bears both constitutional and moral obligations to protect disabled prisoners' rights, ensuring non-discriminatory treatment and facilitating their rehabilitation and societal reintegration.

WHO approves injectable HIV drug lenacapavir for high-risk communities
WHO approves injectable HIV drug lenacapavir for high-risk communities

Business Standard

time7 hours ago

  • Business Standard

WHO approves injectable HIV drug lenacapavir for high-risk communities

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks Apexa Rai New Delhi The World Health Organization (WHO) has released updated guidelines to strengthen global HIV prevention efforts, recommending the use of lenacapavir — a newly approved, long-acting antiretroviral — for high-risk groups and in regions with high infection rates. The recommendation was announced on 14 July at the 13th International AIDS Society Conference (IAS 2025) held in Kigali, Rwanda. It marks a milestone in HIV prevention, following the recent approval of lenacapavir by the United States Food and Drug Administration (FDA) as a twice-yearly injectable pre-exposure prophylaxis (PrEP) treatment. Initially approved in 2022 for treating HIV, lenacapavir demonstrated strong efficacy in prevention trials, offering near-complete protection against infection. The drug has now become a central pillar of WHO's revised prevention strategy. What is Lenacapavir? Lenacapavir (LEN) is a long-acting HIV medicine developed by New Delhi-based Gilead Sciences. It belongs to a new class of drugs known as capsid inhibitors, which work by disrupting multiple stages in the HIV replication cycle. Approved for treatment in 2022 and prevention in 2024, LEN is the first PrEP injection that can be administered just twice a year. This long-acting injectable offers a powerful alternative to daily oral pills and other shorter-acting methods. With only two doses annually, LEN could be transformative, particularly for individuals facing challenges related to daily adherence, healthcare access, or stigma. WHO supports LEN usage against AIDS 'While an HIV vaccine is still elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk,' said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 'The launch of WHO's new guidelines, alongside the FDA's recent approval, marks a critical step forward in expanding access to this powerful tool,' he said. He further reiterated WHO's commitment to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible WHO's endorsement of LEN reflects a shift towards expanding and diversifying prevention tools in order to give individuals better choices. Challenges ahead in HIV prevention Seeking simplified access through rapid testing As part of the updated approach, WHO has also recommended a public health model that incorporates simplified HIV testing using rapid diagnostic kits. This will support broader access to long-acting injectable PrEP options such as lenacapavir and cabotegravir (CAB-LA). It will also facilitate community-based delivery via pharmacies, clinics and telehealth platforms. Funding concerns as Trump cuts aid The release of these guidelines coincides with growing concern over declining international aid for HIV programmes. According to the United Nations, around 80 per cent of prevention funding in low- and middle-income countries comes from foreign assistance. In recent months, the United States has sharply reduced its support, including funding for the US Agency for International Development (USAID) and the President's Emergency Plan for AIDS Relief (PEPFAR) — the largest commitment ever made by any nation towards tackling a single disease. The impact of these cuts is already evident. In Nigeria, for instance, the number of people receiving PrEP dropped from roughly 40,000 late last year to fewer than 7,000 in April 2025, according to UNAIDS data. A recent United Nations report warned that millions more could die of HIV-related causes by 2029 if current funding levels are not restored. Although 25 of 60 low- and middle-income countries surveyed intend to raise their domestic HIV budgets in the coming year, the report cautioned that these increases are unlikely to fully compensate for lost international support. Gilead Science shows hope amid setbacks In a promising development, Gilead Sciences announced an agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir at cost, with no profit margin. This pricing model reflects only the cost of production and delivery, CNN reported. In the United States — currently the only country where lenacapavir is approved for prevention — the drug carries an annual list price of $28,218, a figure comparable to existing PrEP treatments, according to the company.

Health ministry asks government departments to display details about oil, fats in snacks
Health ministry asks government departments to display details about oil, fats in snacks

Scroll.in

time7 hours ago

  • Scroll.in

Health ministry asks government departments to display details about oil, fats in snacks

The Union health ministry has urged all government departments, autonomous bodies and ministries to display details about how much oil, sugar and fats are present in snacks, including samosas and pakoras, in their cafeterias and meeting rooms to tackle obesity, The Hindu reported. In a letter on June 21, Union Health Secretary Punya Salila Srivastava said that 'we are proposing display of Sugar and Oil Boards initiative to promote healthier dietary habits in various settings', PTI reported. Srivastava said that the boards would serve as 'visual behavioural nudges in schools, offices, public institutions, etc. displaying key information about hidden fats and sugars in everyday foods'. The health secretary also urged them to print health messages on all official stationery, including letterheads, envelopes, notepads, folders and publications to reinforce daily reminders on fighting obesity. The letter asked the departments, ministries and autonomous bodies to provide healthier options, including fruits and vegetables, in their offices, while limiting the availability of sugary drinks and high-fat snacks, The Hindu reported. It further called for the promotion of physical activities such as the use of stairs, short exercise breaks and facilitating walking routes. Srivastava referred to a study published in The Lancet in March, which predicted that nearly 45 crore Indians could be overweight or obese by 2050. This would mean that India is likely to have the second-highest number of overweight and obese people in the world, after China. Obesity significantly increases the risk of non-communicable diseases such as diabetes, heart disease, kidney and liver problems, and certain cancers. It also affects mental health, mobility and quality of life. The campaign undertaken by the ministry will first be rolled out at the All India Institute of Medical Sciences in Nagpur, The Hindu reported. An unidentified ministry official told the newspaper that the campaign was expected to expand to other cities later this year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store